Coronary Artery Disease

Gene therapy study under way

Published in Gene Therapy Weekly, April 24th, 2003

A 56-year-old East Brunswick, New Jersey, man has become the first patient to enter a Robert Wood Johnson University Hospital research study of a gene therapy product, called Ad5FGF-4, designed to stimulate the body's natural ability to grow new blood vessels.

Dr. Abel Moreyra, MD, director of the Heart Center of New Jersey, administered a one-time, intracoronary injection by heart catheterization, giving the patient either Ad5FGF-4 or a placebo. In this double-blind study, neither Moreyra nor the patient knew whether the injection contained the investigational gene therapy product or the placebo.

After receiving the injection, the patient will be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry